CG Oncology Inc

For the period ended Dec 31, 2023. Filed Mar 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 26, 2024

CGON$74.74-1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K Summary

None.

EXHIBIT INDEX

ExhibitNumber · Exhibit Description · Incorporated by Reference · FiledHerewith
Form · Date · Number
3.1	Amended and Restated Certificate of Incorporation	S-1/A	01/18/24	3.3
3.2	Amended and Restated Bylaws	S-1	01/02/24	3.4
4.1	Specimen stock certificate evidencing the shares of common stock	S-1/A	01/18/24	4.1
4.2	Amended and Restated Investors’ Rights Agreement, dated July 28, 2023, as amended, by and among the Registrant and certain of its stockholders	S-1/A	01/18/24	4.2
4.3	Description of Registered Securities				X
10.1#	CG Oncology, Inc. 2015 Equity Incentive Plan, as amended, and form of stock grant agreement and form of stock option agreement thereunder	S-8	01/26/24	10.1
10.2#	CG Oncology, Inc. 2022 Incentive Award Plan and form of stock option agreement, form of stock option agreement (early exercise) and form of restricted stock unit agreement thereunder	S-8	01/26/24	10.2
10.3#	CG Oncology, Inc. 2024 Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder	S-8	01/26/24	10.3
10.4#	CG Oncology, Inc. 2024 Employee Stock Purchase Plan	S-8	01/26/24	10.4
10.5#	Non-Employee Director Compensation Program	S-1/A	01/18/24	10.5
10.6†	Development and License Agreement, dated March 11, 2019, between the Lepu Biotech Co., Ltd. and the Registrant	S-1	01/02/24	10.6
10.7†	License and Collaboration Agreement, dated March 26, 2020, between Kissei Pharmaceutical Co., Ltd. and the Registrant	S-1	01/02/24	10.7
10.8†	First Amendment to the License and Collaboration Agreement, dated September 15, 2022, between Kissei Pharmaceutical Co., Ltd. and the Registrant	S-1	01/02/24	10.8
10.9#	Form of Indemnification Agreement for Directors and Officers	S-1	01/02/24	10.9
10.10#	Annual Bonus Plan	S-1	01/02/24	10.11
10.13	Amended and Restated Employment Agreement, effective March 15, 2023, between Arthur Kuan and the Registrant	S-1	01/02/24	10.12
10.14#	Amended and Restated Employment Agreement, effective December 13, 2023, between Arthur Kuan and the Registrant	S-1	01/02/24	10.13
10.15#	Employment Agreement, effective July 9, 2023, between Ambaw Bellete and the Registrant	S-1	01/02/24	10.14
10.16#	Amended and Restated Employment Agreement, effective December 13, 2023, between Ambaw Bellete and the Registrant	S-1	01/02/24	10.15
10.17#	Employment Agreement, effective August 14, 2023, between Vijay Kasturi and the Registrant	S-1	01/02/24	10.16

10.18#	Amended and Restated Employment Agreement, effective December 13, 2023, between Vijay Kasturi and the Registrant	S-1	01/02/24	10.17
10.19#	Employment Agreement, effective January 16, 2024, between Corleen Roche and the Registrant	S-1/A	01/18/24	10.18
23.1	Consent of Independent Registered Public Accounting Firm				X
31.1	Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X
31.2	Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X
32.1*	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				X
32.2*	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				X
97#	Policy for the Recovery of Erroneously Awarded Compensation	S-1	01/02/24	10.10

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.